Comparison
CJC-1295 vs. GHRP-2
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
no data
158861-67-7
Molecular weight
3647.3 g/mol
817.93 g/mol
Half-life
144 h
0.5 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACD-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
4
of which in humans
2
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
3
1